Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension (OSCAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00139698 |
|
Recruitment Status :
Completed
First Posted : August 31, 2005
Last Update Posted : December 5, 2018
|
Sponsor:
Pfizer
Information provided by:
Pfizer
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Essential Hypertension | Drug: olmesartan alone or in combination with hydrochlorothiazide | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 410 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension |
| Study Start Date : | September 2005 |
| Study Completion Date : | July 2006 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Hypertension
Primary Outcome Measures :
- Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Secondary Outcome Measures :
- Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject has mild to moderate hypertension
Exclusion Criteria:
- History of secondary hypertension
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00139698
Locations
| Colombia | |
| Pfizer Investigational Site | |
| Medellin, Antioquia, Colombia | |
| Pfizer Investigational Site | |
| Barranquilla, Atlantico, Colombia | |
| Pfizer Investigational Site | |
| Cartagena, Atlantico, Colombia | |
| Pfizer Investigational Site | |
| Bogota, Cundinamarca, Colombia | |
| Pfizer Investigational Site | |
| Cali, Valle Del Cauca, Colombia | |
| Ecuador | |
| Pfizer Investigational Site | |
| Escobedo, Guayas, Ecuador | |
| Pfizer Investigational Site | |
| Quito, Pichincha, Ecuador | |
| Hong Kong | |
| Pfizer Investigational Site | |
| NT, Hong Kong | |
| Pfizer Investigational Site | |
| Shatin, NT, Hong Kong | |
| Indonesia | |
| Pfizer Investigational Site | |
| Jakarta, Indonesia, 10430 | |
| Pfizer Investigational Site | |
| Jakarta, Indonesia, 11420 | |
| Pfizer Investigational Site | |
| Jakarta, Indonesia | |
| Pfizer Investigational Site | |
| Surabaya, Indonesia, 60286 | |
| Malaysia | |
| Pfizer Investigational Site | |
| Seremban, Negeri Sembilan, Malaysia, 70300 | |
| Pfizer Investigational Site | |
| Kuching, Sarawak, Malaysia, 93586 | |
| Philippines | |
| Pfizer Investigational Site | |
| San Juan, Metro Manila, Philippines | |
| Pfizer Investigational Site | |
| Quezon, Philippines | |
| Singapore | |
| Pfizer Investigational Site | |
| Singapore, Singapore, 119074 | |
| Pfizer Investigational Site | |
| Singapore, Singapore, 169608 | |
| Taiwan | |
| Pfizer Investigational Site | |
| Guei-Shan Shiang, Tau-Yuan Shian, Taiwan, 333 | |
| Pfizer Investigational Site | |
| Kaohsiung, Taiwan, 813 | |
| Pfizer Investigational Site | |
| Taipei, Taiwan, 106 | |
| Pfizer Investigational Site | |
| Taipei, Taiwan, 112 | |
| Thailand | |
| Pfizer Investigational Site | |
| Khet Rajathevee, Bangkok, Thailand, 10400 | |
| Pfizer Investigational Site | |
| Bangkok, Thailand, 10400 | |
| Pfizer Investigational Site | |
| Bangkok, Thailand, 10700 | |
| Pfizer Investigational Site | |
| Chiang Mai, Thailand, 50200 | |
| Turkey | |
| Pfizer Investigational Site | |
| Bornova/Izmir, Turkey, 35100 | |
| Pfizer Investigational Site | |
| Haseki/Istanbul, Turkey, 34390 | |
| Pfizer Investigational Site | |
| Sihhiye/Ankara, Turkey, 06100 | |
| Pfizer Investigational Site | |
| S¿hhiye/Ankara, Turkey, 06100 | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
Additional Information:
| ClinicalTrials.gov Identifier: | NCT00139698 |
| Other Study ID Numbers: |
A0021002 |
| First Posted: | August 31, 2005 Key Record Dates |
| Last Update Posted: | December 5, 2018 |
| Last Verified: | December 2018 |
Additional relevant MeSH terms:
|
Hypertension Essential Hypertension Vascular Diseases Cardiovascular Diseases Hydrochlorothiazide Olmesartan Antihypertensive Agents Diuretics |
Natriuretic Agents Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists |